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Drug use and cognitive function in residents of homes for the elderly
• J.G .E . Janzing, M.A. van 't  Hof and F.G. Zitm an
I
Introduction
The cognitive function of elderly people is vulnerable 
to the effects of drugs. Experimental studies have 
shown that the use of drugs such as trihexyphenidyl 
[1], amitriptyline [2] and benzodiazepines [3 4] 
results in impaired cognition in elderly subjects. In 
addition, Tune et al., using an in vitro assay, found 
that a large number of the most frequently prescribed 
drugs in elderly subjects have levels of anticholinergic 
activity which are sufficient to cause cognitive impair­
ment [5].
Up till now, most of the evidence of the relation­
ship between drug use and cognitive function comes 
from experimental studies. In a clinical study on this 
subject Larson et al. concluded that a high prescrip­
tion rate of drugs, the use of hypnotic agents and the 
use of antihypertensives are the cause of cognitive 
impairment in elderly subjects [6], Unfortunately 
these authors studied groups of drugs rather than 
specific types of drugs. Furthermore their results do 
only pertain to subjects referred for cognitive prob­
lems.
The aim of the present study is to investigate pos­
sible associations between the use of the most fre­
quently prescribed types of drugs and cognitive func­
tion in a naturalistic setting. Because, according to 
experimental studies, the use of CNS drugs is particu­
larly associated with cognitive impairment in elderly 
subjects, we investigate this relationship in detail.
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Subjects
The study was performed at 5 homes for the elderly in 
the region of Nijmegen, the Netherlands. Homes for 
the elderly offer board, lodging and care to the elder­
ly who are no longer able to cope on their own 
because of minor ailments. Not being medical institu­
tions, these homes do not offer nursing. The study 
and the informed consent procedure were reviewed 
and approved by the Review Board of the University 
Hospital Nijmegen and the boards of the 5 participat­
ing homes. All the residents were provided with writ­
ten information and were invited to participate.
Informed consent was obtained from the subjects 
themselves or, in case of severe cognitive impairment, 
from close relatives of the subjects. It was considered 
unethical to use data from residents who refused par­
ticipation.
Drug inventory
Information on daily drug use was given by the resi­
dents and was checked using the records of the staff.
The names of the drugs taken daily were recorded 
and classified according to the Anatomical 
Therapeutic Classification system (ATC) [7]. For all 
drugs the daily prescribed doses were registered.
Drugs for external use only and over-the-counter 
drugs were excluded from the study. Vitamins were Accepted January 1997 
only included when they were prescribed by a doctor.
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Abstract
In order to investigate the relationship between cognitive 
function and daily used drugs in the elderly we performed an 
observational, cross-sectional study in 5 homes for the elderly 
in the region of Nijmegen, the Netherlands. Participants
scores.
in these
'S* (+4,
In all homes for the elderly the compliance of drug of age and education. Taking into account the num- 
use was high because of supervision by members of ber of tests performed (Bonferroni), we used the sig- 
the staff. nificance level of p <  0.005 instead of p < 0.05.
Assessment of cognitive function
The Mini Mental State Examination (MMSE) was used Results
to measure cognitive function. The MMSE, which was 
originally developed for the detection of dementia 
and delirium [8], is a valuable instrument for the reg­
istration of clinically significant drug effects on cogni­
tive function [9-11].
The following areas of cognitive function are cov­
ered by the MMSE: orientation, immediate memory, 
attention and calculation, short term recall, under­
standing language, following commands and writing 
and copying designs. Reliability and validity of the 
MMSE have been repeatedly demonstrated. The max­
imum score of 30 points reflects normal cognitive 
function. A MMSE score below 24 is considered to be 
indicative for cognitive dysfunction [9]. In computing 
correlations with drug use, we used the total scores 
on the MMSE. Because other studies have shown that 
both age and education can be considered to be con­
founding variables [12 13], all relationships between 
drug use and MMSE scores were computed adjusting 
for the effects of these variables.
The MMSE was administered in the private rooms 
of the residents. It was arranged that apart from the 
resident and the interviewer no people were present 
during test administration. Furthermore we took care 
that there was enough light and that the test could 
be completed in a quiet atmosphere.
Interviewers were 4 medical students who had 
completed a training by a neuropsychologist and had 
performed interrater reliability studies (the Pearson's 
correlation coefficients of the total MMSE scores 
ranged from 0.97 to 0.99).
Statistical analysis
Partial correlations and regression equations were 
computed using SPSS-X [14]. Two-tailed tests of sig­
nificance were used for the computation of partial 
correlations between total MMSE scores and the use
The homes had 616 residents of whom 497 (80.7%) 
were willing to participate. The group of participants 
comprised 384 women (77.3%) and 113 men 
(22.7%). The mean age was 83.5 (sd = 6.5) years. A 
total of 365 (73.4%) of the participants were wid­
owed, 64 (12.9%) were married, 59 (11.9%) had 
never been married and 9 (1.8%) were divorced. The 
mean duration of education, measured as the time 
the participants attended day school, was 7.0 (sd = 
2.1) years.
The mean number of different drugs taken daily 
was 3.3 (sd -  2.4); 205 residents (41.2%) used more 
than 3 different drug types a day and 58 residents 
(11.7%) did not use any drugs on a daily basis. The 
mean total score on the MMSE was 21.5 (sd = 5.9). 
Fifty-two percent of the residents scored below the 
cutoff point of 24. The range of total MMSE scores 
was 0 to 30.
Table 1 lists the names, the mean daily doses and 
range of daily doses of the drugs which were used 
daily by more than 5% of the participants. For these 
drugs a variable of drug use was created: a score of 1 
was attributed in case of daily use, a score of 0 indi­
cated that the drug was not taken daily by the sub­
ject. Partial correlations were computed between 
drug use and total MMSE scores. Furthermore, using 
the doses of subjects with daily drug use, we comput­
ed partial correlations between drug dose and total 
MMSE score. These results are also presented in Table
1. The only significant correlation found was between 
daily use of metoproiol and total MMSE score, indi­
cating that metoproiol use was associated with a bet­
ter cognitive function.
In order to compute the proportion of variance in 
the MMSE scores which could be explained by the 
use of these drugs, a multiple regression analysis was 
performed with the total MMSE score serving as the
of a number of specific drugs adjusting for the effects dependent variable. First we entered the variables age
Table 1 The relationship between drug use and total MMSE score
Drug Number of Mean daily Range of daily Drug use and Drug dose and
users dose (mg) dose (mg) MMSE score* MMSE scored
Furosemide 141 53 20-160 -0.06 0.01
Digoxin 86 0.156 0.0625-0.375 -0.06 -0.05
Triamterene 67 49 25-100 0,01 -0.13
Isosorbide-dinitrate 66 51 15-125 0.09 -0.01
Oxazepam 64 14 5-35 0.02 -0.15
Temazepam 63 . 1 13t • ; ► 10-30 -0.00 -0.09
Acetylsalicylic acid 00to 99 40-320 -0.01 0.12
Carbasalate calcium, > , 47 257 80-1200 -0.07 0.28
Paracetamol 41 1250 250-3000 -0.07 0.38
Metoproiol 39 92 25-400 0.15* 0.28
Verapamil 28 163t* • » 40-320 0.01 0.06
Correlations between drug use and total MMSE scores partîalljng out for age and education, computed for all residents, 
t Correlations between drug use and total MMSE scores partialling out for age and education, computed only for the users of 
the drug.
* p = 0.001.
and education to control for their effects. 
Subsequently the variables of drug use were entered 
simultaneously. Age and education together account­
ed for 5.0%, whereas the 11 variables of drug use 
explained only an additional 2.9% of the total vari­
ance in the MMSE scores.
To investigate if the relationship between metopro-
lol and total MMSE scores could be accounted for by 
a higher prescription rate of total drugs or cardiovas­
cular drugs in elderly with a better cognitive function, 
the partial correlations between the total MMSE 
scores and the number of drugs daily taken and 
between the total MMSE scores and the number of 
cardiovascular drugs used daily were computed, 
adjusting for age and education. Both correlations 
were non-significant (r -  0.04 and r = 0.02 respecti­
vely).
The frequency distribution of CNS drugs used daily 
is as follows: anti-epileptic drugs (ATC class N03) in 
10 subjects (2.0%), anti-parkinson drugs (ATC class 
N04) in 12 subjects (2.4%), psycholeptics (ATC class 
N05) in 199 subjects (40.0%) and psychoanaleptics 
(ATC class N06) in 28 subjects (5.6%). No subject 
used trihexyphenidyl, 7 subjects (1.4%) used amitrip­
tyline and benzodiazepines were used by 185 sub­
jects (37.2%). Adjusting for age and education, we 
found no significant partial correlations between the 
total MMSE scores and the daily use of anti-epileptic 
drugs, anti-parkinson drugs, psycholeptics, psycho­
analeptics, amitriptyline and benzodiazepines.
Discussion
Up till now there have been no population-based 
studies on this subject using a naturalistic design, 
including both cognitive impaired and cognitive 
intact elderly and studying different drug types. 
Drug-induced cognitive impairment in elderly sub­
jects has been particularly reported from experimen­
tal studies [1-4].
We measured cognitive function using the MMSE, 
which is sensitive to detect clinically important drug 
effects [9-11]. The total MMSE score has a clearly 
defined clinical value. Our results probably can be 
generalized to other homes for the elderly because 
the population we studied is comparable in demo­
graphic data, rate of cognitive impairment and num­
bers and types of drugs used daily to residents in 
other studies on homes for the elderly [15-18].
Because only a small part of the variance in cogni­
tive function was explained by drug use we conclude 
that the use of frequently prescribed drugs is not 
associated with serious cognitive impairment in the 
residents of homes for the elderly. This limited rela­
tionship might be explained by adequate measures 
taken by prescribes. On the other hand drug- 
induced cognitive impairment in individuals or small 
subgroups is probably difficult to detect in an 'epide­
miological' design.
We found a significant low positive association 
between the use of metoproiol and the total MMSE 
scores. Because both hypertension and arrhytmia are 
considered to be risk factors for cognitive impairment 
(for instance by increasing the risk on cerebrovascular 
disease [19]) the relationship between metoproiol 
and the MMSE scores could hypothetically be 
explained by the anti-hypertensive or anti-arrhytmic
effects of metoproiol. From the literature there is no 
empirical evidence supporting this hypothesis. To our 
knowledge there are no reports on the relationship 
between anti-arrhytmic drug effects and cognitive 
function in elderly subjects. Furthermore, in two epi­
demiological studies, no association was demonstrat­
ed between anti-hypertensive drug treatment and 
cognitive performance in elderly subjects [20 21]. In a 
third study the use of anti-hypertensives was even 
identified as a risk factor for drug-induced cognitive 
impairment [6]. Finally, the present study shows that 
apart from metoproiol the daily use of other anti­
hypertensives or anti-arrhytmics is not associated with 
cognitive function.
In our subjects the use of temazepam and oxaze­
pam was not associated with cognitive function. In a 
clinical study, investigating cognitive-impaired sub­
jects, Larson et al. identified the use of benzodiaze­
pines as a possible cause of drug-induced global cog­
nitive impairment [6]. However, this effect was only 
found for long-acting benzodiazepines. The benzodi­
azepines in our study are short acting and were par­
ticularly used as hypnotics. This could explain our 
negative findings during day-time testing. Our results 
are contradictory to the results of experimental stud­
ies. However, it is difficult to compare our clinical data 
with those studies where the effects of single doses of 
benzodiazepines were studied in healthy elderly sub- 
jects [3 4].
Although it has been demonstrated that a chronic 
intoxication with salicylates can result in cognitive 
impairment in elderly subjects [22], we found no sig­
nificant association between the use or the dose of 
carbasalate calcium or acetylsalicylic acid and the 
total MMSE score. Apparently, in our population 
salicylate intoxication is not a highly prevalent condi­
tion.
We found no association between the use of CNS 
drugs in. general (several ATC groups) and cognitive 
function in our subjects. Although Moskowitz et al. 
demonstrated cognitive impairment in elderly sub­
jects after short-time use of amitriptyline [2], we 
could not demonstrate such a relationship. However, 
the number of residents using this drug is too small to 
draw definite conclusions.
The results of this study should be interpreted with 
caution due to the limitations of the design. It is 
important to state that in contrast to an experimental 
design it is not possible to detect causai relationships 
in an observational cross-sectional study. However, 
the design in the present study is used to detect rela­
tionships of possible clinical importance in the com­
plexity of a naturalistic setting in which the elderly 
with heterogenous problems use a range of different 
drugs. Furthermore, we only investigated the associa­
tions between cognitive function and the most fre­
quently prescribed drugs. Important associations 
between cognitive function and drugs with a lower 
prescription rate in our subjects cannot be excluded.
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